These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Pertwee RG, Fernando SR, Nash JE, Coutts AA. Br J Pharmacol; 1996 Aug; 118(8):2199-205. PubMed ID: 8864562 [Abstract] [Full Text] [Related]
3. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Martin RS, Luong LA, Welsh NJ, Eglen RM, Martin GR, MacLennan SJ. Br J Pharmacol; 2000 Apr; 129(8):1707-15. PubMed ID: 10780977 [Abstract] [Full Text] [Related]
9. AM630, a competitive cannabinoid receptor antagonist. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A. Life Sci; 1995 Nov; 56(23-24):1949-55. PubMed ID: 7776818 [Abstract] [Full Text] [Related]
11. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Ross RA, Brockie HC, Fernando SR, Saha B, Razdan RK, Pertwee RG. Br J Pharmacol; 1998 Nov; 125(6):1345-51. PubMed ID: 9863666 [Abstract] [Full Text] [Related]
12. Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus--longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca2+ and cAMP. Coutts AA, Pertwee RG. Can J Physiol Pharmacol; 1998 Mar; 76(3):340-6. PubMed ID: 9673798 [Abstract] [Full Text] [Related]
13. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. Gifford AN, Ashby CR. J Pharmacol Exp Ther; 1996 Jun; 277(3):1431-6. PubMed ID: 8667207 [Abstract] [Full Text] [Related]
14. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E. Naunyn Schmiedebergs Arch Pharmacol; 2000 Jan; 361(1):19-24. PubMed ID: 10651142 [Abstract] [Full Text] [Related]
15. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Pertwee RG, Stevenson LA, Griffin G. Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090 [Abstract] [Full Text] [Related]
16. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Pertwee RG, Griffin G, Lainton JA, Huffman JW. Eur J Pharmacol; 1995 Sep 25; 284(3):241-7. PubMed ID: 8666005 [Abstract] [Full Text] [Related]
17. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Gifford AN, Samiian L, Gatley SJ, Ashby CR. Eur J Pharmacol; 1997 Apr 18; 324(2-3):187-92. PubMed ID: 9145770 [Abstract] [Full Text] [Related]
18. Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Pertwee RG, Thomas A, Stevenson LA, Maor Y, Mechoulam R. Neuropharmacology; 2005 Jun 18; 48(8):1139-46. PubMed ID: 15910889 [Abstract] [Full Text] [Related]
19. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse. Lay L, Angus JA, Wright CE. Eur J Pharmacol; 2000 Mar 10; 391(1-2):151-61. PubMed ID: 10720647 [Abstract] [Full Text] [Related]
20. Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. Dmitrieva N, Berkley KJ. J Neurosci; 2002 Aug 15; 22(16):7147-53. PubMed ID: 12177210 [Abstract] [Full Text] [Related] Page: [Next] [New Search]